1. Home
  2. TNGX vs AGNCM Comparison

TNGX vs AGNCM Comparison

Compare TNGX & AGNCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • AGNCM
  • Stock Information
  • Founded
  • TNGX 2014
  • AGNCM N/A
  • Country
  • TNGX United States
  • AGNCM United States
  • Employees
  • TNGX N/A
  • AGNCM 53
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • AGNCM Real Estate Investment Trusts
  • Sector
  • TNGX Health Care
  • AGNCM Real Estate
  • Exchange
  • TNGX Nasdaq
  • AGNCM Nasdaq
  • Market Cap
  • TNGX 351.2M
  • AGNCM N/A
  • IPO Year
  • TNGX N/A
  • AGNCM N/A
  • Fundamental
  • Price
  • TNGX $5.63
  • AGNCM $24.64
  • Analyst Decision
  • TNGX Strong Buy
  • AGNCM
  • Analyst Count
  • TNGX 6
  • AGNCM 0
  • Target Price
  • TNGX $12.20
  • AGNCM N/A
  • AVG Volume (30 Days)
  • TNGX 3.3M
  • AGNCM N/A
  • Earning Date
  • TNGX 08-06-2025
  • AGNCM N/A
  • Dividend Yield
  • TNGX N/A
  • AGNCM N/A
  • EPS Growth
  • TNGX N/A
  • AGNCM N/A
  • EPS
  • TNGX N/A
  • AGNCM N/A
  • Revenue
  • TNGX $40,990,000.00
  • AGNCM N/A
  • Revenue This Year
  • TNGX N/A
  • AGNCM N/A
  • Revenue Next Year
  • TNGX N/A
  • AGNCM N/A
  • P/E Ratio
  • TNGX N/A
  • AGNCM N/A
  • Revenue Growth
  • TNGX 10.09
  • AGNCM N/A
  • 52 Week Low
  • TNGX $1.03
  • AGNCM N/A
  • 52 Week High
  • TNGX $12.02
  • AGNCM N/A
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 78.55
  • AGNCM 43.44
  • Support Level
  • TNGX $4.80
  • AGNCM $24.45
  • Resistance Level
  • TNGX $5.96
  • AGNCM $25.36
  • Average True Range (ATR)
  • TNGX 0.51
  • AGNCM 0.18
  • MACD
  • TNGX -0.02
  • AGNCM -0.06
  • Stochastic Oscillator
  • TNGX 92.95
  • AGNCM 20.88

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About AGNCM AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock

AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.

Share on Social Networks: